Skip to main content

Table 3 Incidence of cancer-associated thrombosis by clinical variables

From: Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy

 

Characteristics

No. of cases with CAT (%)

No. of cases without CAT

P value

Age (years)

< 65

106 (1.4)

7,678

< 0.001

 

≥ 65

101 (2.6)

3,829

 

Sex

Female

115 (1.7)

6,850

0.248

 

Male

92 (2.0)

4,657

 

BMI (kg/m2)

< 25.0

140 (1.7)

8,479

0.050

 

≥ 25.0

67 (2.2)

3,028

 

BMI (kg/m2)

< 30.0

202 (1.8)

11,107

0.536

 

≥ 30.0

5 (1.3)

400

 

BMI (kg/m2)

< 35.0

206 (1.8)

11,466

0.528a)

 

≥ 35.0

1 (2.4)

41

 

Platelet count (×103/µL)

< 350

149 (1.6)

9,261

0.002

 

≥ 350

58 (2.6)

2,246

 

Hemoglobin (g/dL)

< 10

34 (3.0)

1,117

0.001

 

≥ 10

173 (1.7)

10,390

 

Leukocyte count (×103/µL)

< 11

166 (1.6)

10,509

< 0.001

 

≥ 11

41 (4.1)

998

 

Chemotherapeutics

High CAT risk

153 (2.3)

6,563

< 0.001

 

No high CAT risk

54 (1.1)

4,944

 

Site of cancerb)

Low CAT risk

71 (1.1)

6,401

< 0.001

 

High CAT risk

87 (2.3)

3,728

 
 

Very high CAT risk

49 (3.6)

1,378

 

Diabetes mellitus

Yes

56 (2.4)

2,308

0.013

 

No

151 (1.6)

9,199

 

Hypertension

Yes

105 (2.3)

4,388

< 0.001

 

No

102 (1.0)

10,419

 

Chronic kidney disease

Yes

23 (3.3)

674

0.002

 

No

184 (1.7)

10,833

 

Preexisting antiplatelet use

Already used

38 (22)

1,229

< 0.001

 

Not used

169 (1.6)

10,278

 
  1. Abbreviations: CAT, cancer-associated thrombosis; BMI, body mass index;
  2. (a) Fisher’s exact test; (b) according to the Khorana score